MP79-16 PTEN EXPRESSION LOSS IS ASSOCIATED WITH AN INCREASED RISK OF CANCER-SPECIFIC MORTALITY AMONG MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY

Abstract

You have accessJournal of UrologyProstate Cancer: Markers II1 Apr 2014MP79-16 PTEN EXPRESSION LOSS IS ASSOCIATED WITH AN INCREASED RISK OF CANCER-SPECIFIC MORTALITY AMONG MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY Michael Gorin, Tamara Lotan, Bruce Trock, Elizabeth Platz, Elizabeth Humphreys, Angelo De Marzo, George Netto, Alcides Chaux, and Misop Han Michael GorinMichael Gorin More articles by this author , Tamara LotanTamara Lotan More articles by this author , Bruce TrockBruce Trock More articles by this author , Elizabeth PlatzElizabeth Platz More articles by this author , Elizabeth HumphreysElizabeth Humphreys More articles by this author , Angelo De MarzoAngelo De Marzo More articles by this author , George NettoGeorge Netto More articles by this author , Alcides ChauxAlcides Chaux More articles by this author , and Misop HanMisop Han More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.2519AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Loss of the PTEN tumor suppressor gene has recently been shown to be associated with an increased risk of biochemical recurrence (BCR) among men with clinically localized prostate cancer treated with radical prostatectomy (RP). Little is known, however, regarding the influence of PTEN on the subsequent risk of disease progression and death among men who have experienced BCR. Thus, the objective of this study was to evaluate PTEN expression status as a risk factor for prostate cancer-specific mortality (PCSM) among men with BCR after RP. METHODS A tissue microarray constructed from men with BCR after RP was analyzed for PTEN expression status by immunohistochemistry. Using a validated scoring system, cases were dichotomized as either normal or markedly decreased/loss. Kaplan-Meier and proportional hazards regression analyses were performed to evaluate PTEN status as an independent predictor of PCSM, with survival measured from date of BCR. RESULTS PTEN expression status was evaluated for 346 men with BCR. During a median follow-up of 8 years (IQR 2-12) from BCR, 75 (21.7%) men died of prostate cancer. Actuarial prostate cancer-specific survival at 10 years after BCR was 78% for men with normal PTEN expression and 65% for men with PTEN expression loss (p < 0.001). After controlling for Gleason sum, pathologic stage, and salvage treatment, PTEN expression loss was associated with a hazard ratio for PCSM of 2.16 (95% CI 1.34-3.51, p = 0.002). CONCLUSIONS Among men with BCR, PTEN expression loss was independently associated with increased risk of PCSM. Because the prognosis for men with BCR is highly variable, PTEN expression, if validated, may prove to be useful to identify men who may benefit the most from salvage therapy. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e935-e936 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Michael Gorin More articles by this author Tamara Lotan More articles by this author Bruce Trock More articles by this author Elizabeth Platz More articles by this author Elizabeth Humphreys More articles by this author Angelo De Marzo More articles by this author George Netto More articles by this author Alcides Chaux More articles by this author Misop Han More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...